Imaging Response to Immunotherapy Combination Therapies in mRCC
Investigators report findings from the largest analysis characterizing objective imaging response among patients with mRCC treated in routine clinical practice.
Immunotherapy
Tislelizumab Shows Promise for High-Risk Nonmuscle-Invasive Bladder Cancer
Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.
Adjuvant Nivolumab Shows Durable Benefit in High-Risk MIUC
Longer follow-up from the CheckMate 274 trial shows nivolumab given after radical surgery for high-risk muscle-invasive urothelial carcinoma maintains a clinically meaningful improvement in disease-free survival.
Immune Checkpoint Inhibitors May Aggravate Proteinuria in mRCC
In a study of patients with mRCC, both TKI and PD-1 inhibitors displayed significant nephrotoxicity.
ICIs May Improve mRCC Outcomes in Cytoreductive Nephrectomy Cases
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
TMB May Help Guide ICI Use in Metastatic Castration-Resistant Prostate Cancer
Immune checkpoint inhibitors were more effective than taxanes in patients with a high tumor mutational burden.
Belimumab May Reduce Organ Damage in SLE, Lupus Nephritis
Belimumab is a monoclonal antibody that inhibits B-lymphocyte stimulator.
DNA Assay May Distinguish Responses to mRCC Immunotherapy
The TARDIS assay could be used in studies to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
Treatment Advances Have Upped Survival in Metastatic Kidney Cancer
Investigators in Austria studied overall survival in 914 patients diagnosed with mRCC from July 1985 to September 2020.
Immune Checkpoint Inhibitors Prolong Survival in mRCC, Real-World Data Show
Use of immune checkpoint inhibitors for any line of treatment was beneficial, investigators reported.
- Loading...
Loading...
Next post in IKCS 2022
Loading... 
Loading...